Bendazac is an oxyacetic acid with anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties. Bendazac acts by preventing protein denaturation and delays the cataractogenic process[1][2].
Bendazac is an anti-inflammatory agent endowed with protein antidenaturant properties effective for various inflammatory skin conditions. Bendazac has been shown to be a strong reacting substrate in a chemical oxidizing system, which mimics a physiological pathway of hydroxy radical generation[2].By using EPR spectroscopy of spin-labelled bovine serum albumin (BSA), Bendazac was shown to prevent the BSA denaturation induced by urea, heat and free radicals produced in the xanthine/xanthine oxidase system[2].
[1]. Balfour JA, et al. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts. Drugs. 1990;39(4):575-596. [2]. Guglielmotti A, et al. Radical scavenger activity of bendazac, an anticataract non-steroidal anti-inflammatory agent. Pharmacol Res. 1995;32(6):369-373. [3]. Musci G, et al. Mechanism of the scavenger-like activity of bendazac. Drugs Exp Clin Res. 1987;13(5):289-292.